When looking for the best stocks to buy and watch, focus on those with rising relative price strength.
One stock that fits that bill is CRISPR Therapeutics (CRSP) stock, which had its Relative Strength (RS) Rating upgraded from 68 to 85 Wednesday.
X
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD’s unique RS Rating measures technical performance by showing how a stock’s price movement over the last 52 weeks compares to that of other stocks on the major indexes.
History reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 as they begin their biggest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Is CRISPR Therapeutics Stock A Buy?
CRISPR Therapeutics stock recently reclaimed its 200-day moving average and is trying to complete a cup without handle with a 72.00 buy point. See if the biotech stock can break out in heavy trading. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips.
The biotech company posted 0% EPS growth last quarter, while sales growth came in at -100%.
CRISPR Therapeutics stock earns the No. 24 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm (AMPH) and HUTCHMED (China) ADR (HCM) are also among the group’s highest-rated stocks. For more industry news, check out “
Biotech And Pharmaceutical Industry And Stock News.”
YOU MAY ALSO LIKE:
Learn How To Time The Market With IBD’s ETF Market Strategy
Find Today’s Best Growth Stocks To Watch With IBD 50
Find The Best Long-Term Investments With IBD Long-Term Leaders
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
